H.C. Wainwright lowered the firm's price target on Voyager Therapeutics to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones, the analyst tells investors in a research note. The company also advanced its NeuroShuttle non-viral delivery technology, with upcoming preclinical and trial data presentations expected to drive potential inflection points, the firm says.
